A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
This is open-label, multicenter, Phase Ib study is designed to evaluate the Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in participants with advanced solid tumors.
Advanced Solid Tumors
DRUG: IBI321
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators., From Baseline until disease progression (up to 2 years)
Progression Free Survival (PFS), According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators., From Baseline until disease progression (up to 2 years)|Overall Survival (OS), From Day 1 to up to 2 years|Percentage of Participants with Adverse Events (AEs) per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, From Day 1 to up to 2 years|Area Under the Concentration-Time Curve (AUC) of IBI321, From Day 1 up to 2 years|Maximum Serum Concentration (Cmax) of IBI321, From Day 1 up to 2 years|Minimum Serum Concentration (Cmin) of IBI321, From Day 1 up to 2 years|Clearance (CL) of IBI321, From Day 1 up to 2 years|Percentage of Participants with Anti-Drug Antibodies (ADAs) to IBI321, From Day 1 up to 2 years|Percentage of Participants with Neutralizing Antibody (Nab) to IBI321, From Day 1 up to 2 years
This is open-label, multicenter, Phase Ib study is designed to evaluate the Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in participants with advanced solid tumors.